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Ventilatory response to CO2 re-breathing before
and after Nocturnal Nasal Intermittent Positive
Pressure Ventilation in patients with chronic
alveolar hypoventilation
C. DELLBORG, J. OLOFSON, C.-H. HAMNEGA˚RD, B.-E. SKOOGH AND B. BAKE
Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Go¨teborg, Sweden
Long-term nocturnal nasal intermittent positive pressure ventilation (NIPPV) has beneficial effects on daytime
PaCO2 in patients with chronic alveolar hypoventilation. Our aim was to investigate if these beneficial effects are
related to improved respiratory drive as measured by ventilatory response to CO2. In 17 hypoventilated patients
(mean age 62 years) we obtained daytime arterial blood gases, nocturnal transcutaneous oxygen saturation,
nocturnal transcutaneous PaCO2, ventilatory response to CO2 re-breathing, spirometry and indices of respiratory
muscle strength before and after 9 months of NIPPV. Patients served as their own controls.
After 9 months of NIPPV day-time PaCO2 decreased from 7?1 kPa to 6?3 kPa, (P50?001) and PaO2 increased
from 8?1 kPa to 9?3 kPa, (P50?01). The changes in morning and daytime PaCO2 and in nocturnal transcutaneous
oxygen saturation were significantly correlated to the changes in several variables derived from the ventilatory
response to CO2 re-breathing. In patients with substantial improvement in daytime PaCO2 we found significant
improvements in ventilatory response to CO2 re-breathing.
The present study confirms the beneficial effect of long-term NIPPV on daytime arterial blood gases. The results
are consistent with the hypothesis that the improvement of daytime PaCO2 is related to improved respiratory drive
observed after NIPPV.
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Patients with chronic alveolar hypoventilation due to
neuromuscular and thoracic wall disorders show impaired
blood gases, especially during sleep (1,2). Nocturnal nasal
intermittent positive pressure ventilation (NIPPV) will
alleviate this nocturnal impairment. Furthermore, NIPPV
has also been shown to improve and even normalize arterial
blood gases during daytime spontaneous breathing (3–5).
The mechanisms involved are not yet determined.
In diseases such as polio or scoliosis, chronic alveolar
hypoventilation is often a consequence of malfunction in the
effector system of the ventilatory process. It is conceivable
that treatment with NIPPV may improve elements of the
effector system e.g. breathing muscles or the mechanicalReceived 7 January 2000 and accepted in revised form 22 June
2000. Published online 8 November 2000.
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0954-6111/00/121154+07 $35?00/0properties of the thorax or lung. On the other hand, the
control system may improve, i.e. regulation of breathing may
be influenced. Several studies have shown that the ventilatory
response to CO2 re-breathing is reduced in neuromuscular
diseases (6–8) but at the start of the present study there were
no data available on the effect of long-term NIPPV treatment
on regulation of breathing in these patients. The aim of the
present study was therefore to investigate the effects of
NIPPV on daytime arterial blood gases, pulmonary function
and ventilatory response to CO2 re-breathing.
Patients and methods
The study was approved by the Committee for Medical
Research Ethics at Go¨teborg University. All participants
gave written informed consent.
PATIENTS
We studied patients living in the western part of Sweden
(approximately 1?5 million inhabitants) who had been
referred to the pulmonary department during a 3-year# 2000 HARCOURT PUBLISHERS LTD
RESPONSE TO CO2 RE-BREATHING BEFORE AND AFTER NIPPV 1155period for evaluation of hypoventilation and for consider-
ing initiation of home mechanical ventilation. Criteria for
inclusion in the study were:
1. Alveolar hypoventilation (repeated daytime
PaCO26?2 kPa) due to status post-polio, healed
pulmonary tuberculosis, scoliosis, other chest wall
deformities or neuromuscular diseases.
2. No signs of infection, exacerbation of obstructive lung
disease or cardiac failure with pulmonary oedema (as
judged by clinical investigation and chest X-ray) for 3
weeks prior to the investigation.
3. Psychosocial ability to handle home mechanical
ventilation. No patient was living at an institution.
Out of 46 patients considered for home mechanical
ventilation 36 fulfilled these criteria and entered the study.
Ventilatory response to CO2 re-breathing was obtained
before treatment with NIPPV in 23 of these patients.
Reasons for not performing these measurements were, for
example, denial to participate or lacking capacity in the
laboratory. Out of these 23 patients, six patients did not
participate in the follow-up investigations after 9 months.
Two patients refused to repeat the test, one patient died,
one patient stopped treatment and two patients were not
able to repeat the investigation. Thus, 17 patients form the
basis of the present report. In Table 1, demographic data,
pulmonary function and daytime arterial blood gases are
shown. Four patients had signs and symptoms of airway
obstruction, but only one of them was treated with
teophyllin. Two patients were smokers and five were ex-TABLE 1. Clinical data of hypoventilated patients studied prior
NO Gender Age Diagnosis Length Weight
(M/F) (years) (cm) (kg)
1 F 63 P.polio 169 50
2 M 46 P.polio 166 69
3 F 70 Scoliosis 139 43
4 F 44 Scoliosis 174 55
5 M 67 Scoliosis 167 52
6 M 58 Scoliosis 172 57
7 F 65 P.TB 157 51
8 F 67 P.polio 172 90
9 M 58 P.polio 182 101
10 F 69 P.polio 167 96
11 M 56 P.TB 166 80
12 F 75 P.TB 170 58
13 F 56 P.polio 166 60
14 F 57 P.TB 164 61
15 M 74 P.TB 177 56
16 M 66 P.polio 172 56
17 M 72 Ankylosing 168 69
spondylitis
Mean value 63 167 65
Patients 1-9 are responders (see Results); Patients 10-17 are
tuberculosis; VC % pred, vital capacity in percent of predicted
predicted normal value; *Transcutaneous mean oxygen saturatismokers. Four patients had peripheral oedemas and eight
patients were treated with diuretics. No patient had a left
ventricular ejection fraction below 50%. Two patients were
wheelchair-dependent due to their underlying disease.
MEASUREMENTS
Daytime arterial blood gas samples were obtained from the
radial artery after at least 30 min rest in supine position.
Analyses of PaO2 and PaCO2 were made with standard
equipment (Radiometer ABL2, Copenhagen, Denmark). All
daytime arterial blood gases were obtained during sponta-
neous breathing both before and after 9 months of treatment.
In bed blood gases: morning blood gases were obtained
during spontaneous breathing before ventilator treatment
was initiated and during NIPPV at the follow-up after 9
months. Transcutaneous oxygen saturation (tc-SO2) during
the night was monitored using a finger probe (Ohmeda
Oxymeter 3700 Louisville, KT, U.S.A.). Transcutaneous
CO2 tension (tc-PCO2) during the night was also monitored
(Capnometer TCM3, Radiometer). The mean tc-SO2 and
the mean tc-CO2 were calculated. Transcutaneous noctur-
nal measurements were obtained during spontaneous
breathing before treatment was initiated and during NIPPV
at the follow-up.
Ventilatory response to CO2 re-breathing was assessed
according to Read (9) as described previously (10). The re-
breathing system consisted of a bag-(8 l)-in-box with a
screen pneumotachygraph in the box wall and a pressure
receptor (Validyne DP 45-14, Engineering Corporation,to NIPPV (n=17)
VC FEV1/VC PaCO2 PaO2 tc-SO2*
(% pred) (%pred) (kPa) (kPa) (%)
44 101 8?8 7?3 88
29 111 6?7 9?7 81
38 101 7?2 6?5 84
33 114 6?6 8?0 85
44 115 7?3 7?2 81
19 67 7?5 6?9 89
29 100 7?4 8?1 90
21 - 6?9 6?1 80
42 120 6?2 7?6 86
47 108 6?7 7?9 82
23 74 6?9 8?2 86
35 71 6?7 8?2 86
31 101 6?6 8?4 91
42 103 6?5 10?5 94
36 86 7?8 7?6 90
20 101 6?6 9?4 92
36 143 8?1 8?5 92
33 94 7?1 8?1 87
poor responders. P.polio, previous polio; P.TB, previous
normal value; FEV1VC (% pred), FEV1/VC in percent of
on during the night.
1156 C. DELLBORG ET AL.Northridge, CA, U.S.A) connected to the box. The bag was
filled with a volume corresponding to the patients VC þ
1?0 l of a gas mixture of 7% CO2 in oxygen. Gas was
sampled at the mouth and analysed for CO2 (Beckman
Medical Gas Analyser, LB-2, Beckman AB, Sweden) and
recorded continuously during re-breathing as was the flow.
The CO2- and flow signals (Validyne DP 45-14, Engineering
Corporation) were calibrated before each investigation.
Recordings were accepted if there were no signs of leakage,
if end tidal PCO2 (et-PCO2) increased by at least 1 kPa and
the rise was linear over time on visual inspection. Two
recordings were required at each occasion. The flow- and
PCO2 signals were fed into a computer and analysed by
computer algorithms programmed with Lab VIEW (Na-
tional Instruments, Austin, TX, U.S.A.). End tidal PCO2,
minute ventilation (VE), tidal volume (VT), breathing
frequency (f), and mean inspiratory flow (VT/Ti, Ti=in-
spiratory time) vs. time were obtained. The slope of VE vs.
et-PCO2 (VE-slope), of VT/Ti vs. et-PCO2 (VT/Ti-slope) were
calculated. Mean values of the variables derived from the
two acceptable recordings at each occasion were used in the
further analysis. The occlusion pressure (Validyne DP 45-
14, Engineering Corporation) 0?1 sec after the start of
inspiration (P0?1) as described by Whitelaw (11) was
obtained during CO2 re-breathing in nine patients. The
pressure signal was fed into the computer and P0?1 was
obtained automatically and displayed vs. et-PCO2.
Spirometry (SensorMedics 922, SensorMedics Corpora-
tion, Yorba Linda, CA, U.S.A.) was performed in
accordance with the ocial statement of the European
Respiratory Society (12). Normal values for vital capacity
(VC) and forced expired volume in 1 sec (FEV1?0) were
predicted according to Berglund et al. (13). Maximal
pressures (Validyne DP 45-36, Engineering Corporation)
at the mouth during an expiratory (MEP) and inspiratory
(MIP) manoeuvre were obtained at functional residual
capacity in the sitting position. The maximal pressures were
defined as the pressure that could be maintained during at
least 1 sec. Normal values were predicted according to
Decramer et al. (14).
Questionnaire: after 9 months of NIPPV a self-report
questionnaire was used to assess hours of ventilator use and
satisfaction with treatment. The latter question had a
response format of 1–7 from very poor to excellent.
MECHANICAL VENTILATION
All patients were ventilated non-invasively via a nasal
mask. Both volume preset (BREAS, Breas Medical,
Go¨teburg, Sweden; PLV-100, Lifecare, Lafayetter, CO,
U.S.A., Monnal-D, L´air Liquide Medical, Le Plessis
Robinson, France) and pressure preset [Bilevel Positive
Airway Pressure (BiPAP), Respironics Inc., Murrysville,
Pennsylvania, U.S.A.] ventilators were used. The reason for
choosing a certain ventilator was mainly practical and
according to the patients preferences. Twelve patients
received volume preset ventilators and five patients received
pressure preset ventilators. Ventilators were used only
during the night and all patients were connected via
standard nasal continuous positive airway pressure (CPAP)masks (Contour mask, Respironics Inc.U.S.A. or Sullivan
mask, Res Med Ltd., North Ryde, NSW, Australia).
NIPPV was started in hospital under the supervision of a
physiotherapist and a physician. Ventilator settings were
determined by overnight monitoring of oxygen saturation,
transcutaneous carbon dioxide tension and arterial blood
gases. Median tidal volume (operator set) in patients with
volume preset ventilators was 0?75 l (range 0?45–0?95 l). In
the pressure preset ventilators median inspiratory positive
airway pressure (IPAP) was 16 (range 16–18) and median
expiratory positive airway pressure (EPAP) was 6 (range 2–
10). The high EPAP pressures were used for patients who
not only had hypoventilation but also a desaturation
pattern suggesting apnoeas during sleep (n=2). No patient
had oxygen added to the ventilator.
THE STUDY PROTOCOL
Before NIPPV patients were admitted to hospital care for
an average of 10 days. During the first 3 days the study
investigations were performed, followed by a NIPPV
training period. At follow-up after 9 months of NIPPV
treatment, patients were again admitted to hospital care for
3 days when measurements were repeated.
Before NIPPV
Daytime arterial blood gases were obtained during sponta-
neous breathing in the afternoon. Evening and morning
blood gases were obtained whilst in bed. Nocturnal
measurements of tc-PCO2 and tc-SO2 were performed
during two consecutive nights. The first night was
considered an adaptation night and the results were not
used in the further analysis. CO2 response test, spirometry
and respiratory muscle function tests were obtained 2–4 h
after leaving bed in the morning on day 2 or 3.
NIPPV treatment:
After approximately 1 week of training most patients were
able to sleep all night with the ventilator and a nocturnal
control of tc-PCO2 and tc-SO2 was obtained. Arterial blood
gases during NIPPV were also obtained. These measure-
ments were repeated after 1–2 months of NIPPV as a
clinical control. The measurements during NIPPV are not
included in the present analysis. In seven patients the
ventilator settings were adjusted during this control. Three
patients needed hospitalization due to breathing problems
during the study period.
After 9 months of NIPPV
Using the same method as before start of treatment with
NIPPV we obtained arterial blood gases during sponta-
neous breathing in the afternoon (daytime), CO2 response
test, spirometry and tests on respiratory muscle function.
Measurements in the evening, during the night and in the
FIG. 1. Original data from one patient demonstrating the
increase of ventilation with increasing end-tidal PCO2
before (^) and after 9 months (*) of NIPPV.
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measurements before start of treatment with NIPPV.
Patients answered the questionnaire.
STATISTICS
For description median and ranges are given.
Comparisons between measurements before and after the
NIPPV-period were made by Wilcoxon signed rank test.
Correlations were analysed by Spearman’s rank correlation
test. A P-value of50?05 was considered significant.
Results
Daytime arterial blood gases obtained after several hours of
spontaneous breathing, had improved and in some patients
even normalized after 9 months of NIPPV (Table 2). The
observed changes in daytime PaCO2 ranged from 70?3 to
2?0 kPa. Four patients deteriorated or improved less than
0?2 kPa.
Morning PaCO2 and nocturnal mean tc-SO2 improved
significantly (P50?001, P50?001, respectively) during
NIPPV, reflecting the ecacy of treatment. Before treat-
ment was initiated the median morning PaCO2 was 7?8 kPa
(range 6?4–9?5 kPa) and the median value for the patients
nocturnal mean tc-SO2 was 86% (range 80–94%). The
corresponding values on NIPPV at the end of the 9 month
period were for morning PaCO2 6?1 kPa (range 4?1–8?3 k-
Pa) and for nocturnal mean tc-SO2 94% (range 88–98%).
The mean VE-slope was 3?8 lmin716kPa, which is low
compared to published normal values (15) and to results
from 13 healthy subjects investigated at our own laboratory
(mean value 16?6 lmin716kPa; range 7?3–37 lmin716k-
Pa; unpublished data). Figure 1 illustrates original data
from the CO2 re-breathing test in one patient who
improved the ventilatory response after NIPPV. Among
the variables derived from the ventilatory response to CO2
re-breathing, there were no significant differences before
and after 9 months NIPPV (Table 2). However, changes inTABLE 2. Arterial blood gases, lung function and CO2 response i
NIPPV (n=17)
Bef
[Median
Daytime PaCO2 (kPa) 6?9 (6?
Daytime PaO2 (kPa) 8?1 (6?
Daytime standard bicarbonate (mmol l71) 30?3 (27
pH 7?39 (7?
VC (l) 1?2 (0?
MIP (kPa) 2?8 (1?
MEP (kPa) 3?4 (1?
VE–slope (lmin716kPa) 2?3 (0?
VT/Ti–slope (l sec716kPa) 0?075 (0?
P0?1 (kPa kPa71)* 70?22 (–0?5
VC: Vital capacity; MIP: maximal inspiratory pressure; MEP: mventilatory response to CO2 re-breathing after 9 months of
NIPPV correlated significantly to the corresponding
changes in blood gases. The changes in VT/Ti-slope
correlated significantly to changes in daytime PaCO2
(P=0?05, r=70?48) (Fig. 2). Furthermore, ecacy of
treatment (measured as changes in morning PaCO2 and
mean nocturnal oxygen saturation) related to changes in
ventilatory response to CO2 re-breathing. Changes in mean
nocturnal oxygen saturation correlated to changes in VT/
Ti-slope (P50?01, r=0?63) and changes in morning PaCO2
correlated to changes in VE-slope (P50?05 r=70?52)
(Fig 3).
There was a statistically significant improvement in vital
capacity, but not in maximal inspiratory or expiratory
pressure after 9 months of NIPPV (Table 2).n patients with hypoventilation before and after 9 months of
ore After P
(range)] [Median (range)]
2–8?8) 6?2 (5?2–7?8) 50?001
1–10?5) 8?8 (7?4–12?1) 50?01
?6–31?3) 28?2 (26–31?2) 50?01
35–7?43) 7?42 (7?34–7?5) NS
5–2?2) 1?4 (0?7–2?6) 50?05
1–5?1) 3?2 (1?4–4?8) NS
2–8?7) 2?8 (0?7–11?7) NS
9–12?9) 2?9 (1?1–14) NS
03–0?43) 0?11 (0?04–0?5) NS
8– 70?075) –0?17 (–0?5– 70?03) NS
aximal expiratory pressure; NS: non-significant; *n=9.
FIG. 2. Correlation between changes in VT/Ti-slope and
changes in daytime PaCO2 (r=70?48, P50?05).
FIG. 3. Correlations between (a) changes in morning
PaCO2 and changes in VE-slope (r=70?52, P50?05) and
(b) changes in mean nocturnal oxygen saturation and
changes in VT/Ti-slope (r=0?63, P50?01)
1158 C. DELLBORG ET AL.All but one patient were positive to continue ventilator
treatment. Median value for satisfaction with treatment
was 6 (range 4–7). Patients reported a median use of NIPPV
of 7 (range 3–8) h per night.
There was a wide range in the observed improvement in
daytime arterial PaCO2. As a post hoc analysis we thereforedivided the study sample in two groups based on this
improvement. We choose the median value of improvement
in daytime PaCO2 in the study sample to obtain groups of
equally size. Furthermore, a change of 0?85 kPa seems to be
of reasonable clinical significance. Thus, patients with an
improvement of at least 0?85 kPa were considered as
responders and those with less improvement as poor
responders.
The responders showed a significant improvement in the
VE-slope, whereas the poor responders did not (Table 3).
Also the VT/Ti-slope improved. All blood gas measure-
ments, VC and MIP improved significantly in this group
(Table 3). The ventilator use was on average 7?0 h per night
(range 4–8 h), and the median satisfaction with treatment
was 5?5 (range 5–7).
Among poor responders there were no statistical
significant changes in CO2 response measurements or
pulmonary function tests. Daytime PaCO2 and standard
bicarbonate improved significantly (P50?05 and –50?05
respectively), but to a smaller extent than in responders
(Table 3). The ventilator use was on average 7?0 h per night
(range 3–8) and the median satisfaction with treatment was
5?5 (range 4–7).
Discussion
The present study confirms that long-time NIPPV improves
daytime PaCO2 in patients with chronic alveolar hypoventi-
lation. There was a significant correlation between changes
in daytime PaCO2 and changes in ventilatory response but
we could not demonstrate a significant improvement in
ventilatory response after treatment in the group as a
whole. However, we found significant improvements in
both VE-slope and VT/Ti-slope in those patients who
responded best to NIPPV treatment in terms of improve-
ment in daytime PaCO2.
There was a considerable variation in the improvement in
daytime PaCO2. Several factors may have contributed to
this, such as various effectiveness of NIPPV, various
progress of the underlying disease or only minor initial
hypoventilation in some of the patients at start of
treatment. Unfortunately, the present data do not permit
exclusion of any of these possibilities.
The improvements of daytime blood gases after long-
term NIPPV may be explained by several potential
mechanisms e.g. improved mechanical properties of the
thorax/lung, relief of muscle fatigue and improved respira-
tory drive. In the present study we found a statistically
significant improvement in VC after NIPPV. The magni-
tude of the VC improvements were, however, small
(from mean 1?2 l to mean 1?3 l) and hardly of any clinical
significance. Furthermore, there were no correlations
between changes in VC and changes in daytime arterial
blood gases. The small changes in VC could be learning
effects or findings by chance. Therefore we do not consider
it likely that improved mechanical properties of the
thorax/lung caused the improved alveolar ventilation after
NIPPV. In agreement with this reasoning is the fact that
TABLE 3. Arterial blood gases, lung function and CO2 response in responders (daytime PaCO2 reduced with 40?85 kPa) and
poor responders ( daytime PaCO2 reduced with 50?85 kPa)
Responders (n=9) Poor responders (n=8)
Before After P Before After P
[Median (range)] [Median (range)] [Median (range)] [Median (range)]
Daytime PaCO2 (kPa) 7?2 (6?2–8?8) 6?0 (5?2–7?5) 50?01 6?7 (6?5–8?1) 6?5 (5?8–7?8) 50?05
Daytime PaO2 (kPa) 7?2 (6?1–9?7) 8?7 (7?4–11?1) 50?01 8?4 (7?9–10?5) 9?2 (7?6–12?1) NS
Daytime standard
bicarbonate (mmol l71)
31 (28–33) 29 (26–30) 50?01 29 (28–31) 28 (26–31) 50?05
pH 7?4 0 (7?35–7?43) 7?43 (7?35–7?50) 50?05 7?40 (7?35–7?43) 7?41 (7?34–7?44) NS
VC (l) 1?2 (0?5–2?2) 1?4 (0?7–2?6) 50?05 1?2 (0?8–1?7) 1?2 (0?9–1?8) NS
MIP (kPa) 2?4 (1?1–5?1) 2?8 (1?4–4?8) 50?05 3?3 (1?7–7?6) 3?2 (1?4–3?7) NS
MEP (kPa) 3?3 (1?2–8?7) 2?1 (1?0–11?7) NS 3?3 (1?7–7?6) 3?8 (0?7–10?4) NS
VE–slope (l min716kPa) 1?9 (0?9–11?4) 2?8 (1?1–14) 50?05 2?7 (0?9–12?9) 3?2 (1?1–6?6) NS
VT/Ti–slope (l sec716kPa) 0?07 (0?03–0?43) 0?11 (0?04–0?49) 50?01 0?10 (0?03–0?41) 0?12 (0?04–0?23) NS
Abbreviations as in Table 2
RESPONSE TO CO2 RE-BREATHING BEFORE AND AFTER NIPPV 1159other authors (4,16) did not find any improvement in VC
after NIPPV.
MIP increased significantly among responders, possibly
reflecting increased strength of inspiratory muscles ex-
plained by relief of muscle fatigue. However, in a study on
patients with respiratory insuciency due to severe chronic
airway obstructive disease, Elliot et al. found no data that
supported the hypothesis that the improved blood gases
during spontaneous ventilation after NIPPV was explained
by relief of muscle fatigue (17). Further, increased muscle
strength as shown in the present study is not necessarily
associated with improved spontaneous ventilation (17),
although this issue might need further consideration. Thus,
there is no support to conclude that increased muscle
strength explains the improved spontaneous ventilation.
In those patients who did not improve daytime PaCO2 or
in whom the improvements were small it seems reasonable
not to expect improvements in ventilatory response. In a
‘post hoc’ analysis we therefore divided the patients into
responders and poor responders based on the improve-
ments of daytime PaCO2.
We found a significant correlation between changes in
daytime PaCO2 and ventilatory response, and significant
improvements in both VE-slope and VT/Ti-slope in the
responder group. These improvements per semay, however,
be explained by improved mechanical properties of the
respiratory system and/or improved respiratory drive. The
CO2 response method does not, unfortunately, allow for
this distinction. Improvements of mechanical properties
have not been substantiated by other studies (16,18) and the
effects in the present study were very small. Thus, we
consider it highly unlikely that improved mechanical
properties would fully explain the improved response to
CO2 re-breathing in the group who responded to long-term
NIPPV by improvement of daytime PaCO2. P0?1 isconsidered to be more closely related to central drive than
ventilatory response to CO2. Unfortunately, there were too
few observations in each of the two groups to allow
statistical analyses of P0?1. However, in the absence of
substantial improvement of lung mechanics, improved
respiratory drive is consistent with the present results, at
least as a contributing mechanism.
It is generally accepted that chronic hypercapnia is
associated with a reduced sensitivity to CO2. The patients in
the present study were hypercapnic at inclusion and showed
very low ventilatory response to CO2 re-breathing. NIPPV
alleviated nocturnal hypoventilation. CO2 sensitivity may
have become regained under these circumstances. Though
speculative, this is in line with the correlations found
between ecacy of treatment (nocturnal mean tc-SO2 and
morning PaCO2) and improvements in ventilatory response.
During preparation of this report, Annane et al. published
data which support this hypothesis (16). They could
demonstrate an improvement in ventilatory response to
CO2 re-breathing in their study sample while we could
demonstrate improvement only among responders. Com-
parison of baseline data reveals no major differences in
arterial blood gases, vital capacity or maximal inspiratory
or expiratory pressures. Values of ventilatory response at
baseline were lower in the study by Annane compared to
our results. Values similar to ours were registered after 1
year of treatment in their study.
Annane’s and our studies differed in study sample. Our
study sample includes patients with healed pulmonary
tuberculosis and such patients were not included in
Annane’s study. In our responder group there was only
one patient with healed pulmonary tuberculosis while there
were four in the poor responder group. Among these four
patients there were three with signs and symptoms of
airways obstruction as well. Patients with airways obstruc-
1160 C. DELLBORG ET AL.tion may have different mechanisms contributing to the
hypoventilation. Another difference between the studies
was the mode of ventilation. All patients were using
volume-cycled ventilators in the study by Annane while
we used both volume-cycled and pressure preset ventilators.
Non-invasive ventilation was given exclusively in our study
while some patients were ventilated via tracheotomy in the
study by Annane. However, both studies showed correla-
tions between decreased PaCO2 and improvement in
ventilatory response after long-term NIPPV.
In summary we have found increased ventilatory
responses to CO2 re-breathing in patients with a substantial
improvement of daytime PaCO2 after NIPPV. We also
found correlations between the increase in ventilatory
response and indices of ecacy of treatment. In the absence
of a substantial improvement of the respiratory mechanical
properties we consider improved respiratory drive the most
likely explanation for the improved ventilatory response
and for improved daytime blood gases after NIPPV.
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